MedTrace Logo

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

NCT06333769 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-08-15

No results posted yet for this study

Summary

To explore the complete response (CR) rate of modified short-course radiotherapy combined with CAPOX and tislelizumab for locally Advanced Mid-low Rectal Cancer

Conditions

  • Mid-low Rectal Cancer

Interventions

RADIATION

Short-course Radiotherapy

Rectal lesion + metastatic lymph nodes, GTV 30Gy/5Fx. Pelvic lymphatic drainage area, CTV 22.5Gy/5Fx.

DRUG

Tislelizumab

Tislelizumab：200mg，d1，q3w，2 cycles.

DRUG

Capecitabine

Capecitabine：1000mg/m2，d1-14，bid, q3w, 2 cycles.

DRUG

Oxaliplatin

Oxaliplatin：130mg/m2, d1, q3w, 2 cycles

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-12
Primary Completion
2025-08-10
Completion
2025-08-14

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06333769 on ClinicalTrials.gov